Limits...
A multi ‐ biomarker follow ‐ up study of patients with multiple sclerosis

View Article: PubMed Central - PubMed

ABSTRACT

Objectives: This study aimed to examine the levels of the macrophage marker sCD163 and other biomarkers at the time of diagnosis of patients with either clinically isolated syndrome (CIS) or relapsing‐remitting multiple sclerosis (RRMS), and assess relation to clinical indicators of prognosis, disease activity (DA), and changes in the levels of these biomarkers at follow‐up.

Materials and methods: The clinical status and MRI were reevaluated in 56 patients more than 1 year after diagnosis with a median follow‐up time of 2 years. Levels of biomarkers in serum and cerebrospinal fluid (CSF) samples were evaluated by enzyme‐linked immunosorbent assays.

Results: There was no significant difference in time to DA between patients with CIS and RRMS. A high sCD163 ratio (>0.07) was significantly (P = 0.04) associated with time to DA in the untreated patient group. In 21 patients reevaluated with serum and CSF samples, the sCD163 ratio levels decreased from 0.068 to 0.054 (P = 0.026) in the CIS/RRMS‐treated group. The CSF CXCL13, CXCL13 ratio, CSF neurofilament light polypeptide and osteopontin levels also decreased significantly in the CIS/RRMS‐treated group.

Conclusions: The levels of all biomarkers changed concurrently with MS treatment. The sCD163 ratio was identified as a potential novel marker for time to DA.

No MeSH data available.


Related in: MedlinePlus

Biomarker levels in treated or untreated patients. Changes in the CSF and serum levels in the follow‐up cohort in treated and untreated patients are shown. In the far left column (A) we present the levels of CSF sCD163, serum sCD163, and ratio sCD163 for treated and untreated patients at the time of diagnosis and after a minimum of 1 year follow‐up time. In the columns (B–E) to the right, data are shown for CXCL13, NEO, NfL, and OPN. Each graph shows the biomarker levels in treated or untreated patients with CIS and RRMS. U‐tests (Mann–Whitney nonparametric test) of the difference between diagnostic and follow‐up levels are marked by a bar and corresponding P‐values. Abbreviations: CIS, clinically isolated syndrome; RRMS, relapsing‐remitting MS; NEO, neopterin; NfL, neurofilament light polypeptide; OPN, osteopontin.
© Copyright Policy - creativeCommonsBy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5036432&req=5

brb3509-fig-0004: Biomarker levels in treated or untreated patients. Changes in the CSF and serum levels in the follow‐up cohort in treated and untreated patients are shown. In the far left column (A) we present the levels of CSF sCD163, serum sCD163, and ratio sCD163 for treated and untreated patients at the time of diagnosis and after a minimum of 1 year follow‐up time. In the columns (B–E) to the right, data are shown for CXCL13, NEO, NfL, and OPN. Each graph shows the biomarker levels in treated or untreated patients with CIS and RRMS. U‐tests (Mann–Whitney nonparametric test) of the difference between diagnostic and follow‐up levels are marked by a bar and corresponding P‐values. Abbreviations: CIS, clinically isolated syndrome; RRMS, relapsing‐remitting MS; NEO, neopterin; NfL, neurofilament light polypeptide; OPN, osteopontin.

Mentions: Changes in the CSF and serum levels of the biomarkers during follow‐up are shown in Figure 4. In the first section of Figure 4, we present the levels of CSF sCD163, serum sCD163, and ratio sCD163 for 13 treated and eight untreated patients with CIS/RRMS at the time of diagnosis and after a minimum of 1 year follow‐up time. In the following sections in Figure 4, we present the data for CXCL13, NfL, NEO, and OPN, further described in detail in Supplementary Data Tables S22 and S23 and Figure S1.


A multi ‐ biomarker follow ‐ up study of patients with multiple sclerosis
Biomarker levels in treated or untreated patients. Changes in the CSF and serum levels in the follow‐up cohort in treated and untreated patients are shown. In the far left column (A) we present the levels of CSF sCD163, serum sCD163, and ratio sCD163 for treated and untreated patients at the time of diagnosis and after a minimum of 1 year follow‐up time. In the columns (B–E) to the right, data are shown for CXCL13, NEO, NfL, and OPN. Each graph shows the biomarker levels in treated or untreated patients with CIS and RRMS. U‐tests (Mann–Whitney nonparametric test) of the difference between diagnostic and follow‐up levels are marked by a bar and corresponding P‐values. Abbreviations: CIS, clinically isolated syndrome; RRMS, relapsing‐remitting MS; NEO, neopterin; NfL, neurofilament light polypeptide; OPN, osteopontin.
© Copyright Policy - creativeCommonsBy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5036432&req=5

brb3509-fig-0004: Biomarker levels in treated or untreated patients. Changes in the CSF and serum levels in the follow‐up cohort in treated and untreated patients are shown. In the far left column (A) we present the levels of CSF sCD163, serum sCD163, and ratio sCD163 for treated and untreated patients at the time of diagnosis and after a minimum of 1 year follow‐up time. In the columns (B–E) to the right, data are shown for CXCL13, NEO, NfL, and OPN. Each graph shows the biomarker levels in treated or untreated patients with CIS and RRMS. U‐tests (Mann–Whitney nonparametric test) of the difference between diagnostic and follow‐up levels are marked by a bar and corresponding P‐values. Abbreviations: CIS, clinically isolated syndrome; RRMS, relapsing‐remitting MS; NEO, neopterin; NfL, neurofilament light polypeptide; OPN, osteopontin.
Mentions: Changes in the CSF and serum levels of the biomarkers during follow‐up are shown in Figure 4. In the first section of Figure 4, we present the levels of CSF sCD163, serum sCD163, and ratio sCD163 for 13 treated and eight untreated patients with CIS/RRMS at the time of diagnosis and after a minimum of 1 year follow‐up time. In the following sections in Figure 4, we present the data for CXCL13, NfL, NEO, and OPN, further described in detail in Supplementary Data Tables S22 and S23 and Figure S1.

View Article: PubMed Central - PubMed

ABSTRACT

Objectives: This study aimed to examine the levels of the macrophage marker sCD163 and other biomarkers at the time of diagnosis of patients with either clinically isolated syndrome (CIS) or relapsing‐remitting multiple sclerosis (RRMS), and assess relation to clinical indicators of prognosis, disease activity (DA), and changes in the levels of these biomarkers at follow‐up.

Materials and methods: The clinical status and MRI were reevaluated in 56 patients more than 1 year after diagnosis with a median follow‐up time of 2 years. Levels of biomarkers in serum and cerebrospinal fluid (CSF) samples were evaluated by enzyme‐linked immunosorbent assays.

Results: There was no significant difference in time to DA between patients with CIS and RRMS. A high sCD163 ratio (>0.07) was significantly (P = 0.04) associated with time to DA in the untreated patient group. In 21 patients reevaluated with serum and CSF samples, the sCD163 ratio levels decreased from 0.068 to 0.054 (P = 0.026) in the CIS/RRMS‐treated group. The CSF CXCL13, CXCL13 ratio, CSF neurofilament light polypeptide and osteopontin levels also decreased significantly in the CIS/RRMS‐treated group.

Conclusions: The levels of all biomarkers changed concurrently with MS treatment. The sCD163 ratio was identified as a potential novel marker for time to DA.

No MeSH data available.


Related in: MedlinePlus